首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1481775

全球真菌性角膜炎治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Fungal Keratitis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 289 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2032 年，全球真菌性角膜炎治療市場的市場規模將從 2023 年的 8.9889 億美元達到近 16.9759 億美元，2024-2032 年研究期間複合年成長率為 7.32%。

真菌性角膜炎的治療涉及控制和消除影響角膜（眼睛的透明外層）的真菌感染。真菌性角膜炎通常由絲狀真菌或酵母菌引起，可由外傷、配戴隱形眼鏡或接觸受污染的土壤或水引起。治療通常涉及抗真菌藥物，例如局部或全身性抗真菌劑，其可以單獨施用或與其他療法（例如清創術、角膜移植或治療性隱形眼鏡）組合施用。治療方法的選擇取決於感染的嚴重程度、致病真菌種類和患者的整體健康狀況等變數。及時診斷和積極治療對於預防視力喪失、角膜疤痕或穿孔等併發症以及恢復眼睛健康和功能至關重要。

市場動態

真菌性角膜炎的發生率不斷增加，特別是在熱帶和亞熱帶地區，推動了對有效且易於使用的治療方案的需求。真菌性角膜炎是由鐮刀菌、麴菌和念珠菌等真菌病原體引起的嚴重眼部感染，如果不及時治療，會導致視力喪失和失明。此外，眼睛外傷、配戴隱形眼鏡以及農業或戶外活動會增加真菌性角膜炎的風險，因此需要及時診斷和適當的治療。此外，聚合酶鏈反應（PCR）檢測和分子定序等診斷技術的進步提高了真菌性角膜炎診斷的準確性和特異性，使臨床醫生能夠根據致病真菌種類制定治療策略。

此外，伏立康唑、那他黴素和兩性黴素 B 等抗真菌藥物的日益普及正在擴大真菌性角膜炎的治療選擇，使臨床醫生能夠根據感染的嚴重程度和類型選擇最合適的治療方法。此外，醫療保健組織、研究機構和製藥公司之間日益加強的合作推動了創新，並加速了新型抗真菌藥物和真菌性角膜炎治療方式的發展。然而，不斷發展的治療方法和藥物進步可能會在未來幾年挑戰真菌性角膜炎治療市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球真菌性角膜炎治療市場的各個細分市場進行了包容性評估。真菌性角膜炎治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

真菌性角膜炎治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

唑類
棘白菌素
多烯
烯丙胺
其他

按指示

皮癬菌病
麴菌病
念珠菌病
其他

依劑型分類

口服藥物
藥膏
粉末
其他

按配銷通路

醫院藥房
零售藥房
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲真菌性角膜炎治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。真菌性角膜炎治療市場的主要參與者包括Vendor Landscape、諾華公司、輝瑞公司、拜耳公司、賽諾菲、默克公司、F.葛蘭素史克公司、雅培、格倫馬克、安斯泰來製藥公司、Scynexis Inc. 本部分包含競爭格局的整體視圖，其中包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概覽、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按藥品類別分類的市場吸引力分析
- 按指標進行的市場吸引力分析
- 按劑型分類的市場吸引力分析
- 按配銷通路分類的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球真菌性角膜炎治療市場分析：按藥物類別

按藥物類別概述
歷史和預測數據
按藥物類別分析
唑類
棘白菌素
多烯
烯丙胺
其他

第 6 章：全球真菌性角膜炎治療市場分析：按適應症分類

按指示概述
歷史和預測數據
按指標分析
皮癬菌病
麴菌病
念珠菌病
其他

第 7 章：全球真菌性角膜炎治療市場分析：按劑型

按劑型概述
歷史和預測數據
按劑型分析
口服藥物
藥膏
粉末
其他

第 8 章：全球真菌性角膜炎治療市場分析：按分銷管道

配銷通路概覽
歷史和預測數據
按配銷通路分析
醫院藥房
零售藥房
其他

第 9 章：全球真菌性角膜炎治療市場分析：按地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 10 章：真菌性角膜炎治療公司的競爭格局

真菌性角膜炎治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 11 章：公司簡介

頂級公司市佔率分析
市場集中度
Vendor Landscape

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Merck & CO. Inc.

公司簡介
公司收入
產品
最近的發展

F. GSK PLC

公司簡介
公司收入
產品
最近的發展

Abbott

公司簡介
公司收入
產品
最近的發展

Glenmark

公司簡介
公司收入
產品
最近的發展

Astellas Pharma Inc.

公司簡介
公司收入
產品
最近的發展

Scynexis Inc.

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114412

The global demand for Fungal Keratitis Treatment Market is presumed to reach the market size of nearly USD 1697.59 Million by 2032 from USD 898.89 Million in 2023 with a CAGR of 7.32% under the study period 2024 - 2032.

Fungal keratitis treatment involves managing and eliminating fungal infections affecting the cornea, the eye's transparent outer layer. Fungal keratitis, often caused by filamentous fungi or yeast species, can result from trauma, contact lens wear, or exposure to contaminated soil or water. Treatment typically involves antifungal medications such as topical or systemic antifungal agents, which may be administered alone or in combination with other therapies such as debridement, corneal transplantation, or therapeutic contact lenses. The selection of treatment depends on variables such as the severity of the infection, the causative fungal species, and the patient's overall health. Prompt diagnosis and aggressive treatment are integral to preventing complications such as vision loss, corneal scarring, or perforation and restoring ocular health and function.

MARKET DYNAMICS

The increasing incidence of fungal keratitis, particularly in tropical and subtropical regions, drives demand for effective and accessible treatment options. Fungal keratitis is a severe eye infection caused by fungal pathogens such as Fusarium, Aspergillus, and Candida, leading to vision loss and blindness if left untreated. Additionally, ocular trauma, contact lens wear, and agricultural or outdoor activities increase the risk of fungal keratitis, driving the need for timely diagnosis and appropriate treatment. Moreover, advancements in diagnostic techniques such as polymerase chain reaction (PCR) testing and molecular sequencing improve the accuracy and specificity of fungal keratitis diagnosis, enabling clinicians to tailor treatment strategies based on the causative fungal species.

Furthermore, the growing availability of antifungal medications such as voriconazole, natamycin, and amphotericin B is expanding treatment options for fungal keratitis, allowing clinicians to select the most suitable therapy based on the severity and type of infection. Additionally, the increasing collaboration between healthcare organizations, research institutions, and pharmaceutical companies drives innovation and accelerates the development of novel antifungal agents and treatment modalities for fungal keratitis. However, evolving treatment methods and pharmaceutical advancements may challenge the growth of the fungal keratitis treatment market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of fungal keratitis treatment. The growth and trends of fungal keratitis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the fungal keratitis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Azoles
Echinocandins
Polyenes
Allylamines
Others

By Indication

Dermatophytosis
Aspergillosis
Candidiasis
Others

By Dosage Form

Oral Drugs
Ointments
Powders
Others

By Distribution Channel

Hospital Pharmacies
Retails Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Fungal Keratitis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Fungal Keratitis Treatment market include Vendor Landscape, Novartis AG, Pfizer, Inc., Bayer AG, Sanofi, Merck & CO., Inc., F. GSK PLC, Abbott, Glenmark, Astellas Pharma, Inc., Scynexis Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. FUNGAL KERATITIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Dosage Form
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL FUNGAL KERATITIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. Azoles Historic and Forecast Sales By Regions
5.5. Echinocandins Historic and Forecast Sales By Regions
5.6. Polyenes Historic and Forecast Sales By Regions
5.7. Allylamines Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL FUNGAL KERATITIS TREATMENT MARKET ANALYSIS BY INDICATION

6.1. Overview By Indication
6.2. Historical and Forecast Data
6.3. Analysis By Indication
6.4. Dermatophytosis Historic and Forecast Sales By Regions
6.5. Aspergillosis Historic and Forecast Sales By Regions
6.6. Candidiasis Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL FUNGAL KERATITIS TREATMENT MARKET ANALYSIS BY DOSAGE FORM

7.1. Overview By Dosage Form
7.2. Historical and Forecast Data
7.3. Analysis By Dosage Form
7.4. Oral Drugs Historic and Forecast Sales By Regions
7.5. Ointments Historic and Forecast Sales By Regions
7.6. Powders Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL FUNGAL KERATITIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data
8.3. Analysis By Distribution Channel
8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
8.5. Retails Pharmacies Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL FUNGAL KERATITIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE FUNGAL KERATITIS TREATMENT COMPANIES

10.1. Fungal Keratitis Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF FUNGAL KERATITIS TREATMENT INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Vendor Landscape
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Novartis AG
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Pfizer Inc.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Bayer AG
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Sanofi
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Merck & CO. Inc.
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. F. GSK PLC
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Abbott
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Glenmark
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Astellas Pharma Inc.
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. Scynexis Inc.
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments